Analytical Data
-
Gene name
HMGB3
- Application
-
Alternative Names
HMGB3;HMG2A;HMG4;High mobility group Protein B3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O15347
-
Expression Region
1-200aa
-
AA Sequence
MAKGDPKKPK GKMSAYAFFV QTCREEHKKK NPEVPVNFAE FSKKCSERWK TMSGKEKSKF DEMAKADKVR YDREMKDYGP AKGGKKKKDP NAPKRPPSGF FLFCSEFRPK IKSTNPGISI GDVAKKLGEM WNNLNDSEKQ PYITKAAKLK EKYEKDVADY KSKGKFDGAK GPAKVARKKV EEEDEEEEEE EEEEEEEEDE
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
High Mobility Group Box 3 (HMGB3) is a non-histone chromosomal protein that plays a crucial role in regulating DNA organization and accessibility, influencing various cellular processes such as transcription, replication, and DNA repair. Research has indicated that HMGB3 is involved in the development and progression of several cancers, making it a potential target for therapeutic interventions. As a member of the high mobility group (HMG) family, HMGB3 possesses a characteristic DNA-binding domain that allows it to interact with nucleic acids, facilitating the modulation of chromatin architecture. Recent studies have shown that recombinant HMGB3 proteins can be produced and purified for in-depth functional analyses, which have advanced our understanding of its mechanistic roles in cellular pathways and disease states. The characterization of HMGB3 at the molecular level has opened new avenues in epigenetic research and cancer biology, paving the way for the development of HMGB3-targeted therapies. Consequently, the generation and analysis of recombinant HMGB3 proteins serve as foundational steps in elucidating its biological functions and exploring its potential as a biomarker or therapeutic target in various malignancies.
